Literature DB >> 17091565

Recent advances in human papillomavirus vaccines.

Ali Mahdavi1, Bradley J Monk.   

Abstract

The human papillomavirus (HPV) is one of the most common sexually transmitted infections and the etiologic agent of cervical dysplasia and cancer. Recent research on the safety and efficacy of prophylactic vaccines against HPV has shown promising results with nearly 100% efficacy in preventing persistent infections and cervical dysplasia. Several approaches are being tested in therapeutic vaccine clinical trials whereby E6, E7, or both agents are administered in live viral vectors, as proteins, or in nucleic acid form. Cell-based therapeutic vaccines are also being tested. HPV vaccines have the potential to eradicate a major cancer and source of morbidity around the world.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17091565     DOI: 10.1007/s11912-006-0076-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  32 in total

Review 1.  Human papillomavirus vaccines and prevention of cervical cancer.

Authors:  Kathrin U Jansen; Alan R Shaw
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Authors:  L Muderspach; S Wilczynski; L Roman; L Bade; J Felix; L A Small; W M Kast; G Fascio; V Marty; J Weber
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.

Authors:  Cheng-Tao Lin; Ya-Chea Tsai; Liangmei He; Roanne Calizo; Hung-Hsueh Chou; Ting-Chang Chang; Yung-Kuei Soong; Chien-Fu Hung; Chyong-Huey Lai
Journal:  J Biomed Sci       Date:  2006-04-29       Impact factor: 8.410

Review 5.  Immune responses to human papillomavirus.

Authors:  Margaret Stanley
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

6.  HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

Authors:  Alessandro D Santin; Stefania Bellone; Michela Palmieri; Antonella Ravaggi; Chiara Romani; Renata Tassi; Juan J Roman; Alexander Burnett; Sergio Pecorelli; Martin J Cannon
Journal:  Gynecol Oncol       Date:  2005-10-24       Impact factor: 5.482

Review 7.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

8.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  The natural history of type-specific human papillomavirus infections in female university students.

Authors:  Harriet Richardson; Gail Kelsall; Pierre Tellier; Hélène Voyer; Michal Abrahamowicz; Alex Ferenczy; François Coutlée; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-06       Impact factor: 4.254

10.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.